Vangsgaard Stensgaard (brushshovel32)

The recurrence rate of benign endometrial polyps after a hysteroscopic polypectomy is low, between 0% and 15%. There are limited follow-up duration data on recurrence factors for benign polyps after hysteroscopic polypectomy, including recurrences with Versapoint® versus resectoscope. This study aims to estimate the rate of symptomatic recurrence following hysteroscopic polypectomy and to analyze the possible risk factors involved with Versapoint® versus resectoscope. We designed a retrospective cohort study in a tertiary university hospital in Seville (Spain) which looked at the results of polypectomy with a 9-mm resectoscope on 42 women between 2008 and 2015 compared to 151 women using Versapoint® during 2014. The rate of first recurrence was 24.35%. There was a strong positive correlation between the recurrence and the follow-up duration (odds ratio [OR] = 2.58; 95% confidence interval [CI] = 1.68-5.04; = 0.000), the polyps causing abnormal uterine bleeding (OR = 2.5; 95% CI 1.1-3; = 0.04), and a polyp size >15 mm (OR = 1.63; 95% CI = 1.3-3.1; = 0.02). There were no statistical differences in polyps' recurrence among the types of hysteroscopic polypectomy ( > 0.05). The main risk factors for recurrence were polyps causing abnormal uterine bleeding, size, and follow-up duration. The main risk factors for recurrence were polyps causing abnormal uterine bleeding, size, and follow-up duration. The purpose of this study was to investigate transvaginal mesh treatment and its effect on the quality of life of Turkish patients with pelvic organ prolapse (POP). Turkish patients with POP were invited to participate in this study, and all the participants underwent prolapse surgery. The clinical outcomes, including effectiveness of the treatment and changes in the quality of life, were measured by the short form-36 survey. The data were analyzed using SPSS version 23. To analyze differences in the quality of life at the three aforementioned points in time, a paired sample -test was used. The results indicated that participants' quality of life increased after surgery. Some quality of life domains (i.e., vitality and mental health) as well as physical and mental health summary scores increased. Overall, transvaginal mesh treatment significantly improved the quality of life of Turkish patients with POP. Women who undergo transvaginal mesh treatment will have positive changes in the quality of life. Women who undergo transvaginal mesh treatment will have positive changes in the quality of life. Here, we compare the success of percutaneous transcatheter sclerosant alcohol therapy (PTSAT) for the postoperative treatment of benign pelvic cysts that occurred after gynecologic surgery. The study is a retrospective case-control trial. Gynecological patients who had symptoms due to postoperative pelvic cysts and received PTSAT after gynecologic surgery, between October 2008 and January 2018, were examined in a single training and research hospital in Turkey. Some factors were investigated for associations with postoperative pelvic cyst formation in patients who underwent gynecologic operations for malignancies or benign conditions. Statistical analysis used The association between two independent and nonnormally distributed continuous variables was analyzed with the Mann-Whitney U-test. Spearman's rho correlation analysis was conducted to determine the correlation of two nonnormally distributed variables. Chi-square (or Fisher's exact test, when more suitable) was used to examine the correlation between categorical variables. Statistically significant differences were found in terms of the average age was higher in patients with malignancies, and the average postoperative pelvic cyst detection time was higher in patients with benign pelvic cysts. While all patients were treated with PTSAT